Introduction
The nucleoside adenosine exerts its biological function via four cell surface G protein-coupled receptors (GPCRs); A 1 , A 2A , A 2B and A 3 (Fredholm et al., 2001; Hill et al., 2014) . These receptors have been implicated in a wide range of biological processes, including regulation of the sleepewake cycle (Huang et al., 2007) , regulation of immune cell function (Ohta and Sitkovsky, 2001) , locomotion (Yang et al., 2009 ) and response to hypoxia (Wan et al., 2008) . In turn, the dysregulation of these processes can lead to a range of different pathological states such as Parkinson's (Jenner et al., 2009 ) and Alzheimer's (Chen et al., 2007) diseases, autoimmune disorders (Ohta and Sitkovsky, 2001 ) and tissue damage following reperfusion injury (Wan et al., 2008) . These receptors therefore represent attractive drug targets (Chen et al., 2013) .
A greater understanding of the precise downstream signal induced by an agonist, and the subsequent regulation of GPCR function, may allow development of more effective drugs. The adenosine receptors signal through different G proteins, with the A 1 and A 3 receptors (A 1 R and A 3 R) predominately coupling to G i/o and A 2A and A 2B receptors (A 2A R and A 2B R) coupling to G s . It has also been shown that different agonists can activate different downstream signalling cascades (Verzijl and Ijzerman, 2011) . Understanding this signalling bias may allow compounds to be developed that target one signalling pathway over another (Kenakin, 2012) . The four adenosine receptors show marked differences in their regulation in response to agonist treatment. The A 2A R, A 2B R and A 3 R receptors have all been shown to desensitize rapidly upon agonist treatment, with A 3 R desensitization the most rapid (Palmer et al., 1994; Peters et al., 1998; Trincavelli et al., 2000) . A 2A R, A 2B R and A 3 R are phosphorylated by G protein-receptor kinases (GRKs) which lead to the recruitment of arrestins and subsequent sequestration from the plasma membrane (Ferguson et al., 2000; Mundell et al., 1998 Mundell et al., , 2000 . In contrast, the A 1 R desensitizes much more slowly and although the agonist stimulated receptor shows enhanced affinity for GRKs it is unclear if phosphorylation actually occurs (Nie et al., 1997; Ramkumar et al., 1991) . It has long been thought that internalization of a receptor leads to termination of the agonist-induced signalling but recent studies have challenged this view. It has been shown that some receptors can continue to signal to the cAMP pathway even after sequestration from the plasma membrane (Boutin et al., 2012; Mullershausen et al., 2009; Werthmann et al., 2012) . One way to understand the internalization of a GPCR and the termination of the signal is through the use of fluorescent ligands.
Fluorescent ligands for GPCRs (Vernall et al., 2014) have become increasingly used for studying various aspects of receptor pharmacology Stoddart et al., 2013) . These ligands allow the visualization of dynamic processes such as receptor internalization, trafficking and diffusion characteristics in the cell membrane (Stoddart et al., 2015, in this issue) . Many different fluorescent ligands for the adenosine receptors have been developed that retain both affinity for the receptor and their agonist or antagonist properties (Kozma et al., 2013b) . Although the fluorescent agonist-based probes that have been previously developed retained potency and efficacy, their imaging characteristics, such as the need for wash steps and the level of non-specific binding, limit their applications in longer-term dynamic studies. It has been shown for the A 2A R and the A 3 R that fluorescent agonists can induce clustering of the receptor within the cell but the fluorescent ligands used in these studies needed to be removed from the cells prior to visualization (Brand et al., 2008; Kozma et al., 2013a) . To allow the dynamic process of receptor internalization to be fully studied, a fluorescent agonist that does not need to be removed is advantageous as this allows the co-localization of the receptoreligand complex with various proteins involved in the internalization process to be studied. The choice of fluorophore used to label the agonist can influence the ability of the compound to be visualized in the continued presence of unbound ligand. A redemitting BODIPY fluorophore is an ideal candidate for use in fluorescent ligands as it is brighter in non-aqueous environments, such as the plasma membrane and therefore specific cell surface fluorescence can be more easily visualized (Baker et al., 2010; May et al., 2010; May et al., 2011) .
The present study aimed to improve the imaging properties of the existing adenosine receptor agonist ABEA-X-BY630 (Middleton et al., 2007) to allow its use in long-term imaging studies through the incorporation of a peptide linker; an approach previously shown to improve the affinity, subtype selectivity and also reduce non-specific membrane binding of fluorescent adenosine receptor antagonists (Vernall et al., 2013) . The newly synthesized fluorescent agonists developed in this study were functionally characterised at each of the adenosine receptors, as well as for agonistinduced internalization at the A 1 R and A 3 R, and arrestin3 recruitment at the A 3 R. The data indicated improved properties for monitoring receptor internalization of untagged adenosine receptors.
Experimental details

Materials
G418, Lipofectamine and Optimem were obtained from Life Technologies (Paisley, UK), foetal calf serum (FCS) from PAA Laboratories (Wokingham, UK) and Lglutamine from Lonza (Basel, Switzerland). NECA [5-(N-ethylcarboxamido) adenosine] and MRS1220 [N-[9-Chloro-2-(2-furanyl)[1,2,4]-triazolo[1,5-c]quinazolin-5-yl] benzene acetamide] were purchased from Tocris Bioscience (Bristol, UK). 6-(((4,4-Difluoro-5-(2-thienyl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl) aminohexanoic acid, succinimidyl ester (BY630-X-SE) was purchased from Molecular Probes ® (Invitrogen, UK). All other chemicals and reagents were obtained from SigmaeAldrich (Gillingham, UK).
Synthesis of fluorescent ligands
Detailed experimental procedures and compound characterisation are provided in the Supplementary data. In brief, the ABEA pharmacophore and the tripeptides were synthesized independently. The ABEA pharmacophore and the required tripeptide were then coupled in solution-phase, the N-terminal peptide protecting group removed to afford a primary amine and this then coupled to the commercially available BY630-X-SE. Fluorescent compounds were purified using semi-preparative high-performance liquid chromatography and purities of all compounds were determined as being !95%.
Cell culture
Chinese hamster ovary (CHO) cells stably expressing a cAMP response elementsecreted placental alkaline phosphatase (CRE-SPAP) reporter gene expressing the human A 3 R or human A 1 R were produced as previously described. For A 2A R and A 2B R cells lines, CHO CRE-SPAP cells were transfected with cDNA encoding the human A 2A R or A 2B R (Missouri S&T cDNA Resource Center, MO, USA) using Lipofectamine (Life Technologies, Paisley, UK) according to the manufacturer's instructions. Transfected cells were subjected to selective pressure for 2e3 weeks through the addition of 1 mg/mL À1 G418 to the normal growth medium. After this time, the cells were dilution-cloned to obtain cell lines originating from a single cell. To confirm the presence of the receptor, cells were screened for their response to NECA in the CRE-SPAP gene transcription assay. CHO cells expressing A 3 -YFP (Stoddart et al., 2014) and co-expressing A 3 -vYc and arrestin3-vYnL (Stoddart et al., 2014) were generated as described previously. were then incubated for 5 h at 37 C/5% CO 2 . After the 5 h incubation, all medium was removed from the cells and replaced with 40 mL of SFM and incubated for a further 1 h. The plates were then incubated at 65 C for 30 min to destroy the endogenous alkaline phosphatases. After cooling the plates to room temperature, 5 mM 4-nitrophenyl phosphate in a diethanolamine-containing buffer (10% (v/v) diethanolamine, 280 mM NaCl, 500 mM MgCl 2 , pH 9.85) was added to each well.
Plates were incubated for varying times depending on the cell line (A 1 R, 20 min/ 37 C; A 2A R, 10 min/37 C; A 2B R, overnight/room temperature; A 3 R, 20 min/37 C) and then the absorbance at 405 nm was measured using a Dynex MRX plate reader (Chelmsford, MA, USA).
Automated imaging of receptor internalization
A 1 -GFP or A 3 -YFP expressing cells were grown to confluency in 96-well clearbottomed, black-walled 96-well plates (mclear base, Greiner Bio One, Stonehouse, UK). On the day of the experiment, normal growth medium was removed and fresh SFM added to the cells containing increasing concentrations of NECA or BY630-X-(D)-A-(D)-A-G-ABEA and incubated for 1 h at 37 C/5% CO 2 . After 1 h, medium and compounds were removed and cells were washed once in phosphate buffer saline (PBS). Cells were then treated with 3% paraformaldehyde solution in PBS for 20 min at room temperature to fix the cells and then washed twice in PBS. The cell nuclei were stained by the addition of the cell permeable dye H33342 (2 mg mL
for 20 min at room temperature, followed by two final washes in PBS. The images were obtained on an ImageXpress Ultra confocal plate reader (Molecular Devices, Sunnyvale, CA, USA). Four central images were obtained per well using a Plan Fluor 40Â NA0.6 extra-long working distance objective. GFP and YFP images were obtained by excitation of the fluorescent protein with a 488 nm laser with emission collected through a 525e550 nm band pass filter and H33342 images by excitation with a 405 nm laser line and emission collected through a 447e460 nm band pass filter. The resulting images were subjected to analysis for granules and nuclei using an algorithm within MetaXpress software (Molecular Devices) to generate a granule count per cell for each image (Kilpatrick et al., 2010) . Granules were identified as having a diameter of between 7 and 15 mm and nuclei as between 6 and 9 mm and the intensity above background was set for each individual experiment.
Confocal imaging
A 3 -YFP, A 3 R or A 3 -vYc/arrestin3-vYnL cells were grown to approximately 80% confluency on 8-well Labtek chambered coverglasses (Nunc Nalgene). Cells were washed twice in HEPES-buffered saline solution (HBSS; 25 mM HEPES, 10 mM glucose, 146 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 2 mM sodium pyruvate, 1.3 mM CaCl 2 , 1 mM NaHCO 3 , pH 7.4) and then fresh HBSS added for analysis. All imaging was performed using a Zeiss LSM710 confocal microscope (Carl Zeiss GmbH, Jena, Germany) fitted with a 63x plan-Apochromat NA1.4 Ph3 oil-immersion objective. For YFP and reconstituted vYFP (BiFC) 488 nm argon laser was used to excite the fluorophore and the emission was detected using a BP505-530 filter.
BY630-X-(D)-A-(D)-
A-G-ABEA was excited using a 633 nm HeNe laser and emission collected through a LP650 filter. Within each experiment, a pinhole diameter of 1 Airy unit was used and the laser power, gain and offset kept constant for each experimental set.
Data analysis
All data were fitted using non-linear regression models within Prism 5 (GraphPad Software, San Diego, CA, USA). A 2A R, A 2B R and A 3 R CRE-SPAP data and internalization data were fitted to the following equation:
where E max is the maximal response, [A] is the concentration of agonist and the EC 50 is the molar concentration of agonist required to generate 50% of the E max . Due to the two component nature of the A 1 R CRE-SPAP data, the following equation was used:
where basal is the response in the absence of agonist, FK is the response to 3 mM FSK in the absence of agonist, IC 50 is the concentration of agonist that inhibits 50% of the FSK response, S MAX is the maximal stimulation of the second component of the curve and EC 50 is for the second component of the curve and is the concentration of agonist that gives half the maximal stimulation.
Results
Four new fluorescent ABEA derivatives were synthesized in this study ( Fig. 1 ; refer to Supplementary data for details). Previously, the adenosine receptor fluorescent agonist, ABEA-X-BY630 had been developed (Middleton et al., 2007) , but this had poor imaging properties in long term studies due high levels of non-specific cytoplasmic uptake. In an effort to improve this fluorescent agonist, we incorporated a peptidic linker as an extra entity between the pharmacophore and the fluorophore. Glycine (gly) was selected as the C-terminal amino acid to enable successful racemization free segment coupling to the ABEA pharmacophore in solution-phase. Alanine-alanine (ala-ala) was used to provide a simple peptidic linker (ala-ala-gly; A-A-G), which also allowed examination of the importance of stereochemistry in the peptide linker. To this end, all four possible combinations of L-and D-ala were used in this ala-ala dipeptide part of the linker
Using CHO cells lines containing a SPAP reporter gene linked to a CRE promoter (Baker et al., 2002) and expressing each of the four adenosine receptor subtypes (A 1 R, A 2A R, A 2B R and A 3 R) the potency and efficacy of the four fluorescent agonists was examined in relation to NECA. All four compounds retained a degree of potency at each of the adenosine receptors (Fig. 2, Table 1 ). The A 2A R and A 2B R are coupled to G s , therefore an increase in the CRE-SPAP response was observed with agonist treatment. As the A 3 R is G i/o coupled, FSK was added to increase the levels of CRE-SPAP via activation of adenylate cyclase, and agonist activation of the receptor resulted in a decrease of the FSK stimulated CRE-SPAP production. The A 1 R also predominantly couples through G i/o but in this CRE-SPAP system a biphasic response is observed, with an inhibition of FSK stimulated CRE-SPAP at low agonist concentrations and an increase in signal over the FSK response at higher agonist concentrations and this has been previously shown to be through coupling to G s (Fig. 4) . In addition, there were low levels of non-specific cytoplasmic fluorescence after 60 min treatment with BY630-X-(D)-A-(D)-A-G-ABEA in both the presence and absence of MRS1220. It is also important to note that these experiments were performed in the continued presence of the fluorescence agonist and there was no requirement for a wash step to observe specific fluorescence from the labelled agonist.
Since the labelling of the A 3 -YFP receptor with BY630-X-(D)-A-(D)-A-G-ABEA appeared very specific, it was possible to use this fluorescence ligand to investigate the internalization of unlabelled receptor using CHO cells stably expressing the wild type human A 3 R. After 5 min of exposure to 100 nM BY630-X-(D)-A-(D)-A-G-ABEA there was predominately cell surface localization of the BY630 fluorescence and this was abolished by pre-treatment of the cells with 1 mM MRS1220, indicating that the fluorescence observed was A 3 R specific (Fig. 5) . After 60 min of agonist treatment, there (Fig. 6 ).
-(D)-A-(D)-A-G-ABEA (C), BY630-X-(L)-A-(L)-A-G-ABEA (-), BY630-X-(L)-A-(D)-A-G-ABEA (△) and BY630-X-(D)-A-(L)-A-G-ABEA (7) were assessed in A 1 R (A), A 2A R (B), A 2B R (C) and
Discussion
Fluorescent ligands for GPCRs are valuable tools to study the localization of receptors in their native environment and to answer important questions on their pharmacology. To enable their use in the study of GPCRs, the pharmacological, spectral and imaging properties of the ligand need to be optimized for specific applications. In this study, our aim was to generate new fluorescent agonists to study the cellular localization of adenosine receptors. This was achieved by incorporating peptide linkers into an existing fluorescent adenosine receptor agonist ABEA-X-BY630 (Middleton et al., 2007) based on a strategy which has been successfully employed with adenosine receptor fluorescent antagonists (Vernall et al., 2013) and which resulted in fluorescent XAC derivatives with improved imaging properties. In the present study, four different ala-ala-gly tripeptide linkers were incorporated between the NECA derivative, ABEA, and the BY630 fluorophore to generate four fluorescent agonists containing each of the possible combinations 
Although NECA is not selective between the four adenosine receptor subtypes, the new peptidelinked fluorescent compounds showed significantly higher potency at the A 1 R and A 3 R in comparison to the A 2A R and A 2B R indicating that the length and composition of the peptide linker may play a role in interacting differently with the different receptor subtypes. This is further confirmed by the differences in the affinity of the stereoisomers as the rank order of the four fluorescent compounds was roughly the same at all four adenosine receptors. The significance of the linker region in generating high affinity and high potency fluorescent ligands has been previously observed for the adenosine A 1 (Baker et al., 2010) and A 3 receptors (Vernall et al., 2013) , the b adrenergic receptors (Baker et al., 2011) , the oxytocin receptor (Karpenko et al., 2014) and the dopamine D 2 receptor (Hounsou et al., 2015) and this present study confirms the importance of the linker as an integral part in the design of fluorescent GPCR ligands.
It was also important to consider the imaging properties of the newly synthesized fluorescent agonist; high affinity or potency does not necessarily equate to specific cell surface imaging (Rose et al., 2012) . The incorporation of the peptide linkers into these adenosine receptor fluorescent agonists resulted in ligands that showed specific membrane binding in cells expressing the A 3 R. This specific imaging was seen in the continued presence of the fluorescent agonist which is in contrast to previously described fluorescent agonist for the adenosine receptors. Kozma and co-workers used the Cy5 labelled A 3 R selective agonist, MRS5218 (Tosh et al., 2009) , and showed accumulation of this agonist within A 3 R expressing cells which they attributed to receptor internalization, although they did not block this internalization with unlabelled ligand and they required the removal of excess fluorescent ligand to generate confocal images (Kozma et al., 2013a) . In addition, it has been shown for the adenosine A 2A receptors that a fluorescent agonist, Alexa488-APEC, could stimulate the internalization of CFP tagged receptor and that the fluorescent ligand was co-localized with this internalized receptor, although these images were obtained after removal of excess fluorescent ligand (Brand et al., 2008) . The ability to measure binding of BY630 labelled compounds in the continued presence of the ligand has been observed for adenosine receptor antagonists Stoddart et al., 2012; Vernall et al., 2012) and agonists and b 2 adrenoceptor antagonists (Baker et al., 2011) . The quantum yield of fluorescent adenosine receptor antagonists containing the BY630 fluorophore have been shown to increase in non-aqueous environments (Baker et al., 2010) suggesting that the high levels of fluorescence observed with BY630-X-(D)-A-(D)-A-G-ABEA indicate that it is a non-polar environment when bound to the A 3 R. This non-polar environment is expected to be the plasma membrane and modelling studies of A 3 R fluorescent antagonists supports the idea that the flurophore is within the lipid bilayer (Vernall et al., 2013) . Fluorescent ligands for the oxytocin receptor using Nile Red as the fluorophore have recently been developed which also display high levels of fluorescence in a non-aqueous environment (Karpenko et al., 2014) . Using BY630-X-(D)-A-(D)-A-G-ABEA we have shown that the fluorescent agonist is in close proximity to the receptor upon sequestration of the receptor from the plasma membrane. Using fluorescent ligands, it has been suggested that the agonist remains bound to the adenosine A 2A (Brand et al., 2008) and A 3 receptors (Kozma et al., 2013a) upon internalization. Upon activation by agonist, the A 3 R receptor has been shown to be phosphorylated at the C-terminus by GRKs (Ferguson et al., 2000; Palmer and Stiles, 2000) which leads to internalization via clathrin coated pits (Trincavelli et al., 2000) . It is unclear if this clathrin dependent mechanism of internalization is dependent of arrestin recruitment as in the rat basophilic leukaemia 2H3 cell line (RBL-2H3) which endogenously express arrestin2, 3 and the A 3 R, no recruitment of arrestin upon agonist stimulation of A 3 R could be detected (Santini et al., 2000) and there was no co-localization of arrestin3 and A 3 R in HEK293 cells transiently expressing both proteins (Ferguson et al., 2002) . We have previously shown that A 3 R can associate with arrestin3 in a concentration-dependent manner in a BiFC assay (Stoddart et al., 2014) . In the present study, we have additionally showed that the fluorescent agonist co-localizes with A 3 R-arrestin3 complexes as visualized by BiFC. This may be due to the fact that BiFC traps the receptor-b arrestin complex, as the association of the two halves of venusYFP is essentially irreversible (Morell et al., 2007) . The presence of an agonist-receptor-arrestin complex has been suggested previously through the presence of high affinity agonist sites (Gurevich et al., 1997) but we believe this is the first study to directly visualize this complex through the use of a fluorescent agonist. The ability to image agonist-receptor-arrestin complex raises the possibility to track agonistereceptor complex throughout the internalization, degradation and recycling processes. Using a biosensor based on a nanobody that only recognises the active conformation of the b 2 AR, Irannejad et al. (2013) recently showed that internalized receptor was still an active confirmation as seen by continued binding of the antibody. This internalized receptor could continue to signal through the cAMP pathway, although they were unable to confirm if the agonist was still bound to the receptor (Irannejad et al., 2013) . By showing that BY630-X-(D)-A-(D)-A-G-ABEA localizes with a receptorearrestin complex, this supports the idea that agonists are still bound to the internalized receptor and sequestration from the plasma membrane may not lead to the direct termination of agonist-induced signalling (Calebiro et al., 2010) . The use of fluorescent agonists that can be imaged without wash steps may help to elucidate the precise point in which the agonist and receptor are no longer bound and termination of agonist induced signalling occurs.
We have shown that BY630-X-(D)-A-(D)-A-G-ABEA can be used to visualize the internalization of untagged receptors, and that this method does not need an further additional chemical modification of the receptor. The presence of a fluorescent protein or epitope tag on a receptor expressed in a host cell can bias the selection of cells that highly express the receptor during generation of the cell line. It is therefore important to confirm in cell lines where the receptor expression level is unknown, and only inferred from functional assays, that receptor internalization can still be visualized with the fluorescent agonist as a first step towards using this tool in a system that endogenously expresses adenosine receptors. This has previously been achieved for the m opioid receptor, through the use of fluorescently labelled dermorphin, to study internalization of endogenously expressed receptors in primary neurons (Arttamangkul et al., 2006) . The A 3 receptor is present in various tissues with particularly high levels of expression in various cells of the immune system, including the microglia and astrocytes (Bjorklund et al., 2008; Ohsawa et al., 2012; van der Putten et al., 2009 ). In addition expression of the A 3 receptor has been detected in various areas of the brain including thalamus, hypothalamus (Yaar et al., 2002) and at motor nerve terminals (Cinalli et al., 2013) . We have also recently shown, using a fluorescent adenosine receptor antagonist, that the A 3 receptor can be found in discrete microdomains on human neutrophils which are located at the bottom of membrane projections (Corriden et al., 2013) .
In conclusion, we have demonstrated that BY630-X-(D)-A-(D)-A-G-ABEA is a highly potent agonist of the A 3 receptor which can be used to visualize the internalization of the receptor. In addition, we have shown that the fluorescent agonist co-localizes with internalized receptor-arrestin complexes. The development of this highly specific fluorescent probe will help to understand the regulation of the receptor with future studies and to investigate the role of the receptor in endogenously expressing systems.
